What is WO2012129495 (the oliceridine patent)?
WO2012129495 is a World Intellectual Property Organization (WO) patent publication connected to oliceridine, a drug candidate used for pain. The “WO” number is the international application publication identifier and doesn’t, by itself, tell you whether a given claim covers a method of use, a compound, a formulation, or a specific treatment regimen. To determine the exact scope, you need the claims and the assignee/applicant listed on the publication record.
Who holds the WO2012129495 patent?
The owner/assignee is shown on the WO publication page for WO2012129495. That name matters because later ownership changes can happen through assignments, mergers, or licensing—so the current entity that enforces rights may differ from the original applicant.
When did WO2012129495 publish, and what does that mean for exclusivity?
The “2012” in the publication number reflects the publication year (2012), not the priority date. Patent rights and market exclusivity depend on multiple timelines:
- Priority date (often earlier than 2012)
- Publication date
- Country-by-country filing and grant dates (e.g., US, EP, etc.)
- Any patent term adjustments and extensions (where applicable)
- The drug’s regulatory exclusivity (which is separate from patent expiry)
So the WO publication is an early public signal, but expiry dates require checking the granted patents in each jurisdiction that correspond to that WO application.
How to find the exact country patents linked to WO2012129495
Most WO applications have “family members” filed in different countries. To map the effective enforcement landscape, look up:
- Patent family (INPADOC/Family listing on the WO page)
- Which jurisdictions granted (and the grant numbers)
- The claims that were allowed and the ones narrowed during prosecution
This is the step that turns “WO2012129495 exists” into “this is the patent that actually blocks generic entry in the US/EU/etc.”
How long does the oliceridine patent last (in practice)?
For most pharmaceutical patents, the baseline term is measured from the priority date (commonly 20 years), but actual lifespan can change due to:
- Whether the claims were granted in each jurisdiction
- Patent term adjustments/extensions (especially in the US)
- Regulatory exclusivity that can extend market protection beyond patent expiry
- Additional patents covering different aspects (composition, method of use, specific combinations)
To answer “how long,” you must identify the specific granted member(s) in the target country.
Can biosimilars/generics bypass WO2012129495 before it expires?
Whether a competitor can enter before expiry depends on what WO2012129495 claims:
- If it covers the core active compound or a key method, it typically blocks generic competition.
- If it covers narrower method-of-use or formulation details, a competitor might design around claims (or rely on non-infringing labeling).
- Even when a patent expires, other patents and regulatory exclusivity can still block entry.
A complete view requires checking the full patent family and related patents around oliceridine.
What to check if you’re trying to assess infringement risk
If you’re researching infringement/invalidity, the practical checklist is:
- The exact claim language in the granted patents (not just the WO publication)
- The jurisdiction’s claim interpretation standards
- The competitor’s product details (drug substance, formulation, dosing method)
- Any litigation or prosecution history estoppel that can narrow scope
Where to look up WO2012129495 details quickly
Use the WO publication record for WO2012129495 to pull:
- Publication date and priority date
- Applicant/assignee
- Abstract and claims
- Patent family members (US/EP/etc.) and their grant status
If you tell me what jurisdiction you care about (US, EU, UK, etc.) and whether you want compound vs method-of-use scope, I can guide you to the specific “family member” you should check for the real expiry date.
Sources
I don’t have access to the live patent database in this chat to verify the specific bibliographic data (assignee, claims, priority/grant/expiry) for WO2012129495 without you providing the publication link or the applicant name/jurisdiction. If you share the WO link (or the assignee and target country), I’ll summarize the patent scope and how it affects oliceridine exclusivity.